Bifidobacterium longum spp. infantis

Bifidobacterium longum spp. infantis 35624, originally isolated from the ileal mucosa of an individual free of gastrointestinal disease has been shown to survive transit through the gastrointestinal tract and to exert potent antiinflammatory effects in vivo in animal models. Other homeostatic effects, such as an enhancement of gut barrier function have also been demonstrated and of relevance to potential clinical indication, this organism has also been shown to accelerate intestinal transit and diminish visceral hypersensitivity. Not surprisingly, therefore clinical trials have focused on irritable bowel syndrome where consistent and clinically meaningful benefits have been demonstrated.